FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236367536> ?p ?o ?g. }

• W4236367536 endingPage "406" @default.
• W4236367536 startingPage "406" @default.
• W4236367536 abstract "406 Background: Treatment of metastatic renal cell carcinoma (mRCC) with sunitinib can be associated with toxicity leading to dose reduction. Maintaining adequate sunitinib dosing and avoiding dose interruptions that lower drug levels are essential for optimizing clinical efficacy. Standard sunitinib schedule is 4 weeks of treatment and 2 weeks of rest (schedule 4/2). Empirically in clinical practice, several metastatic RCC patients at The Cleveland Clinic (CCF) have been changed from a 4/2 schedule to a 2 weeks on /1 week off (2/1) schedule after experiencing toxicity in an attempt to maintain daily dose but reduce toxicity. Methods: The medical records of mRCC patients who were changed to a 2/1 schedule of sunitinib at CCF were retrospectively reviewed. Patient toxicity on each schedule was recorded during routine clinic visits and graded according to the Common Toxicity Criteria, version 4.0. Results: 21 patients were identified: 71% male, 78% clear cell histology, and 29% prior systemic therapy. All but one had prior nephrectomy. 95% of patients on the 4/2 schedule had grade 3 or 4 toxicity which led to the schedule change to 2/1. No grade 4 toxicities were observed on the 2/1 schedule, and 33% of patients experienced grade 3 toxicity (p = 0.0001 for comparison of worst grade toxicity on 4/2 versus 2/1). Two of the most common toxicities, fatigue and hand-foot syndrome (HFS), were significantly less frequent on the 2/1 schedule than on the 4/2 schedule (fatigue 52% all grade/33% grade 3 on 4/2 versus 33%/14% on 2/1; HFS 33%/29% on 4/2 versus 14%/0% on 2/1; p =.04 for both). Median overall treatment duration on the 4/2 schedule was 13.5 months (range 1.1-60.6 months) and median overall treatment duration on the 2/1 schedule was 24.4 months (range 1.3 to 67.6+ months). Conclusions: Treatment with sunitinib on a 2/1 schedule is associated with significantly decreased toxicity in patients who initially experience grade 3 or greater toxicity on the 4/2 schedule and can extend treatment duration considerably. Prospective clinical trials are required to define the optimal schedule of sunitinib to balance efficacy and toxicity." @default.
• W4236367536 created "2022-05-12" @default.
• W4236367536 creator A5008174951 @default.
• W4236367536 creator A5025529463 @default.
• W4236367536 creator A5056587248 @default.
• W4236367536 creator A5059251810 @default.
• W4236367536 creator A5068642720 @default.
• W4236367536 creator A5085460226 @default.
• W4236367536 date "2013-02-20" @default.
• W4236367536 modified "2023-10-05" @default.
• W4236367536 title "Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma." @default.
• W4236367536 doi "https://doi.org/10.1200/jco.2013.31.6_suppl.406" @default.
• W4236367536 hasPublicationYear "2013" @default.
• W4236367536 type Work @default.
• W4236367536 citedByCount "6" @default.
• W4236367536 countsByYear W42363675362013 @default.
• W4236367536 countsByYear W42363675362014 @default.
• W4236367536 countsByYear W42363675362015 @default.
• W4236367536 countsByYear W42363675362020 @default.
• W4236367536 crossrefType "journal-article" @default.
• W4236367536 hasAuthorship W4236367536A5008174951 @default.
• W4236367536 hasAuthorship W4236367536A5025529463 @default.
• W4236367536 hasAuthorship W4236367536A5056587248 @default.
• W4236367536 hasAuthorship W4236367536A5059251810 @default.
• W4236367536 hasAuthorship W4236367536A5068642720 @default.
• W4236367536 hasAuthorship W4236367536A5085460226 @default.
• W4236367536 hasConcept C111919701 @default.
• W4236367536 hasConcept C126322002 @default.
• W4236367536 hasConcept C141071460 @default.
• W4236367536 hasConcept C143998085 @default.
• W4236367536 hasConcept C2777288759 @default.
• W4236367536 hasConcept C2777472916 @default.
• W4236367536 hasConcept C2779490328 @default.
• W4236367536 hasConcept C29730261 @default.
• W4236367536 hasConcept C41008148 @default.
• W4236367536 hasConcept C68387754 @default.
• W4236367536 hasConcept C71924100 @default.
• W4236367536 hasConceptScore W4236367536C111919701 @default.
• W4236367536 hasConceptScore W4236367536C126322002 @default.
• W4236367536 hasConceptScore W4236367536C141071460 @default.
• W4236367536 hasConceptScore W4236367536C143998085 @default.
• W4236367536 hasConceptScore W4236367536C2777288759 @default.
• W4236367536 hasConceptScore W4236367536C2777472916 @default.
• W4236367536 hasConceptScore W4236367536C2779490328 @default.
• W4236367536 hasConceptScore W4236367536C29730261 @default.
• W4236367536 hasConceptScore W4236367536C41008148 @default.
• W4236367536 hasConceptScore W4236367536C68387754 @default.
• W4236367536 hasConceptScore W4236367536C71924100 @default.
• W4236367536 hasIssue "6_suppl" @default.
• W4236367536 hasLocation W42363675361 @default.
• W4236367536 hasOpenAccess W4236367536 @default.
• W4236367536 hasPrimaryLocation W42363675361 @default.
• W4236367536 hasRelatedWork W1994344097 @default.
• W4236367536 hasRelatedWork W2061581498 @default.
• W4236367536 hasRelatedWork W2072245035 @default.
• W4236367536 hasRelatedWork W2171237277 @default.
• W4236367536 hasRelatedWork W2527810245 @default.
• W4236367536 hasRelatedWork W2544140097 @default.
• W4236367536 hasRelatedWork W2590524093 @default.
• W4236367536 hasRelatedWork W3021907264 @default.
• W4236367536 hasRelatedWork W3151554875 @default.
• W4236367536 hasRelatedWork W4205243027 @default.
• W4236367536 hasVolume "31" @default.
• W4236367536 isParatext "false" @default.
• W4236367536 isRetracted "false" @default.
• W4236367536 workType "article" @default.